Porton(SZ:300363)2022-12-08 03:10Group 1: Company Strategy and Operations - The establishment of R&D centers in different locations is primarily based on talent considerations [1] - There are significant differences between chemical drug CMO and biological drug CMO in terms of technology and manufacturing equipment, but there is synergy in systems, customer resources, and business models [1] - The company aims to retain the existing team of the target company in any potential acquisition of biological drug CMO [1] Group 2: Financial Performance and Incentives - The termination of the stock incentive plan was due to a significant decline in the stock price, making it difficult to achieve the intended incentive effect, and is unrelated to the company's performance targets [2] - The acquisition of Jiangxi Dongbang Pharmaceutical Co., Ltd. was not affected by the stock price drop, and the asset transfer procedures have been completed [2] - The company has considered acquisition factors in its performance budget for the year [2]